Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is ...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug ...

MarketWatch Sep 26, 2024, 10:49:00 PM ...

Find the latest Cassava Sciences, Inc. SAVA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

He is +2200 in the latest 2025 U.S. Open odds, the fifth-lowest in the 2025 U.S. Open field. Scottie Scheffler, coming off a victory at the Memorial Tournament, is the +280 U.S. Open favorite.

2025 ncaa DI Men's and Women's Outdoor Track and Field championships - Hayward Field - Eugene, OR 12:30/3:30 P.M. Discus Women's ESPN+ 3:30/6:30 p.m. Heptathlon Long Jump Women's ESPN+ 4:45/7:45 p ...

The 2025 outdoor track and field championships continue today with the women's Heptathlon events beginning at 2:45 p.m. ET/11:45 a.m. PT at Hayward Field in Eugene, Oregon. The men's action begins ...